-
-
-
-
-
-
-
Stifel Starts Enliven Therapeutics (ELVN) at Buy
-
-
-
-
-
-
-
Enliven Therapeutics (ELVN) PT Raised to $45 at Mizuho, 'Still an under-rated asset in the CML space'
-
-
-
-
-
-
-
Enliven Therapeutics (ELVN) PT Raised to $48 at H.C. Wainwright
-
-
-
-
-
-
-
Enliven Therapeutics (ELVN) PT Raised to $45 at BTIG, 'We increase our PoS for the ELVN-001 program and remove ELVN-002 from our model for HER2+ solid tumors'
-
-
-
-
-
-
-
Enliven Therapeutics (ELVN) PT Raised to $40 at Baird
-
-
-
-
-
-
-
H.C. Wainwright Starts Enliven Therapeutics (ELVN) at Buy
-
-
-
460,612 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

